Novartis | NVS - Current Liabilities


Novartis reported $27.28B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Bausch Health Companies USD 4.53B 350M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Canopy Growth CAD 98.29M 17.19M Dec/2025
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Drreddys Laboratories INR 1.76B 62.5M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
J&J USD 57.72B 3.59B Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novartis USD 27.28B 4.72B Dec/2025
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Phibro Animal Health USD 281.87M 500K Mar/2026
Prestige Brands USD 120.92M 18.63M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Sanofi EUR 28.35B 9.32B Dec/2025
Supernus Pharmaceuticals USD 373.93M 35.76M Mar/2026
Zoetis USD 2.05B 182M Mar/2026